So Alberto Migliore, professor of Rheumatology at the Catholic University of the Sacred Heart, Tor Vergata and La Sapienza University of Rome and executive director of Si-Guida, the Italian Society for the unified and interdisciplinary management of musculoskeletal pain and algodystrophy
“In the context of this congress, I have the pleasure of presenting the results of an international consensus, organized and conducted by us, to define the characteristics thanks to which a new intra-articular therapy product can be defined as truly innovative“. This was declared by Alberto Migliore, professor of Rheumatology at the Catholic University of the Sacred Heart, Tor Vergata and La Sapienza University of Rome and executive director of Si-Guida, the Italian Society for the unified and interdisciplinary management of musculoskeletal pain and algodystrophy.
“We found ourselves faced with the fact that many new drugs are being produced, but what is really needed are products that surpass the current ones, their effectiveness, the effectiveness time after administration. So here – he explains – that this consensus has tried to identifying aspects that must be respected in order to be able to define a truly innovative product, and therefore push the scientific community, and research within the pharmaceutical companies, towards this level of novelty and increase in the effectiveness of the products”.
“Under the aegis of Guida we have also created a questionnaire on early osteoarthritis – continues Migliore – It is a tool that allows us, through a few questions, to quantify the level of pain and severity. This questionnaire was initially made for osteoarthritis in an advanced stage, but no scientific society had ever taken steps to create one to investigate the first symptoms, the first stages, and therefore evaluate the extent of the damage and the response in the initial stages. Now this has finally been done. Not only that, we have also started the national validation process: this means that this questionnaire, which is international, will be translated and validated in many countries. I hope that it will soon be used by all my colleagues, so that our patients, in the first stage of the disease, can be identified, treated and followed appropriately”, concludes Migliore.
Other topics of the Si-Guida National Congress include: Update on the biology of acute and chronic pain; lectures on the organizational aspects of chronic pain management in Italy and in the world (first day); diagnostics of chronic pain syndromes; Long-Covid syndrome; novelties in the therapy of arthrosis and algodystrophy; pain and neurological diseases; diagnostic and therapeutic difficulties in fibromyalgia; focus on osteosarcopenia (second day). Finally, the third and final day of the congress gives space to the regional groups. Experiences and local clinical cases are presented, from Triveneto to Sicily, relating to low back pain, infiltrative therapy and arthrosis, algodystrophy and bone edema, sarcopenia.
Source-www.adnkronos.com